Prophylaxis News and Research

RSS

Challenges in identifying high risk patients for preeclampsia using USPSTF guidelines

Preeclampsia (PE) is a hypertensive disease that complicates 7-10% of pregnancies. While recent advances in understanding the underlying causes of PE have been made, predicting its occurrence has historically been difficult because it is a complex condition that likely results from a variety of causes and can present in different ways.

17 Jul 2025

Many HIV-exposed newborns miss preventive treatment after birth

Newborns exposed to HIV during pregnancy or birth should receive preventive antiretroviral medication immediately after delivery to reduce the risk of transmission from mother to child.

16 Jul 2025

New WHO guidelines recommend injectable lenacapavir for HIV prevention

The World Health Organization (WHO) released today new guidelines recommending the use of injectable lenacapavir (LEN) twice a year as an additional pre-exposure prophylaxis (PrEP) option for HIV prevention, in a landmark policy action that could help reshape the global HIV response.

14 Jul 2025

Research highlights an increase in informal use of doxyPEP/PrEP among key populations in the Netherlands

New research analyzing an online survey of 1,633 respondents found 15% recent use of doxycycline post- and pre-exposure prophylaxis (doxyPEP/PrEP) among men who have sex with men (MSM), transgender and gender diverse people in the Netherlands according to a recent study published by Eurosurveillance.

4 Jul 2025

Twice-yearly injection could transform HIV prevention efforts

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A once-daily pill named PrEP, or pre-exposure prophylaxis, has been a stalwart for HIV prevention-but only if people take it consistently and can routinely access a pharmacy.

3 Jul 2025

Partial match stem cell transplants show strong survival rates

Blood cancer patients who may have previously struggled to find a donor for transplantation now have more options.

26 Jun 2025

IL-6 and CRP offer limited boost for predicting infections after lung cancer surgery

Early postoperative levels of IL-6 and CRP are independently associated with infection risk after pulmonary cancer surgery. However, adding these biomarkers to standard clinical predictors provides only limited improvement in infection prediction.

25 Jun 2025

New RSV guideline aims to standardize pediatric care across China

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections (ALRTIs) in children under five and poses a persistent threat to child health worldwide.

20 Jun 2025

New insights into gout management strategies and cardiovascular outcomes

The European Alliance of Associations for Rheumatology - recommends that serum urate should be maintained at <6 mg/dL (360 µmol/L) and <5 mg/dL (300 µmol/L) in those with severe gout.

15 Jun 2025

Study finds sharp rise in HIV prevention medication use among American youth

Eight times more American young adults now take medication to protect them from HIV than a decade ago, a new study finds.

23 May 2025

Maternal RSV vaccine and nirsevimab sharply cut infant hospitalizations, new data show

Widespread use of maternal RSV vaccination and nirsevimab during the 2024–2025 U.S. RSV season led to a significant reduction in RSV-associated hospitalizations among infants aged 0–7 months. The largest benefits were seen in the youngest and most vulnerable infants, particularly during peak winter months.

20 May 2025

UArizona researchers uncover new way to ease postoperative pain in women

University of Arizona Health Sciences researchers identified a potential way to reduce female post-operative pain by inhibiting pituitary prolactin generated by pre-operative stress.

20 May 2025

Repeated antibiotics in preterm infants linked to long-term lung problems

Repeated perinatal antibiotic exposure in very low-birth-weight preterm infants was associated with impaired lung function and a higher risk of asthma at early school age. The findings underscore the need for cautious antibiotic use and targeted respiratory health strategies in this high-risk group.

18 May 2025

Older adults in sub-Saharan Africa face growing HIV epidemic

Prevention and treatment campaigns are not adequately targeting the particular needs of the 50+ years age group.

15 May 2025

Nirsevimab slashes RSV hospitalizations in infants by 78% in real-world study

A Spanish study found that nirsevimab prophylaxis significantly reduced infant hospitalizations, ICU admissions, and severe symptoms linked to RSV and other respiratory viruses. Hospitalizations for RSV dropped by 78% following nirsevimab rollout in Madrid maternity wards.

8 May 2025

Long-acting HIV drug emerges from decades of research and advocacy

In the hunt for a remedy, when the baton is passed from dedicated academic scientists to an innovative company to trusted community advocates, outcomes for society can be especially powerful.

8 May 2025

HIV testing and outreach falter as Trump funding cuts sweep the South

Storm clouds hung low above a community center in Jackson, where pastor Andre Devine invited people inside for lunch. Hoagies with smoked turkey and ham drew the crowd, but several people lingered for free preventive health care: tests for HIV and other diseases, flu shots, and blood pressure and glucose monitoring.

6 May 2025

Clinical trial underway to assess effectiveness and safety of potential Long Covid treatment

A clinical trial is underway to assess the effectiveness and safety of sipavibart, AstraZeneca's long-acting monoclonal antibody designed to provide protection against Covid-19, as a potential treatment for Long Covid, the Nova Southeastern University (NSU) and the Schmidt Initiative for Long Covid (SILC) announced today.

1 May 2025

New recommendations for the treatment of familial Mediterranean fever

In 2016, EULAR - The European Alliance of Associations for Rheumatology - published recommendations on the treatment of familial Mediterranean fever (FMF). Since then, new evidence has become available, so the recommendations have been reviewed and updated.

23 Apr 2025

Marstacimab approved to treat patients aged 12 years and above (weighing at least 35 kg) with hemophilia A or B

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine marstacimab (Hympavzi) to prevent or reduce bleeding in patients 12 years of age and older weighing at least 35 kg with hemophilia A and B.

23 Apr 2025